Published in Biochim Biophys Acta on September 15, 2005
Experimental models of hepatocellular carcinoma. J Hepatol (2008) 1.61
Transcription cofactors TRIM24, TRIM28, and TRIM33 associate to form regulatory complexes that suppress murine hepatocellular carcinoma. Proc Natl Acad Sci U S A (2011) 1.42
Deletion of betaine-homocysteine S-methyltransferase in mice perturbs choline and 1-carbon metabolism, resulting in fatty liver and hepatocellular carcinomas. J Biol Chem (2011) 1.40
Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. J Transl Med (2011) 1.33
Targeting the oncogene and kinome chaperone CDC37. Nat Rev Cancer (2008) 1.32
Downregulation of polo-like kinase 4 in hepatocellular carcinoma associates with poor prognosis. PLoS One (2012) 0.96
Molecular cochaperones: tumor growth and cancer treatment. Scientifica (Cairo) (2013) 0.92
Cell surface Cdc37 participates in extracellular HSP90 mediated cancer cell invasion. PLoS One (2012) 0.88
Genetic variations in plasma circulating DNA of HBV-related hepatocellular carcinoma patients predict recurrence after liver transplantation. PLoS One (2011) 0.80
Chemopreventive potential of Epoxy clerodane diterpene from Tinospora cordifolia against diethylnitrosamine-induced hepatocellular carcinoma. Invest New Drugs (2008) 0.79
An expression signature of phenotypic resistance to hepatocellular carcinoma identified by cross-species gene expression analysis. Cell Oncol (Dordr) (2012) 0.78
Interaction of major genes predisposing to hepatocellular carcinoma with genes encoding signal transduction pathways influences tumor phenotype and prognosis. World J Gastroenterol (2008) 0.77
New insights on the role of epigenetic alterations in hepatocellular carcinoma. J Hepatocell Carcinoma (2014) 0.75
Post-translational deregulation of YAP1 is genetically controlled in rat liver cancer and determines the fate and stem-like behavior of the human disease. Oncotarget (2016) 0.75
O-aminoazotoluene suppresses hepatocyte proliferation in inbred mice susceptible to hepatocarcinogenesis. Dokl Biol Sci (2009) 0.75
Orto-aminoazotoluen induces the expression of the p53 gene in inbred strains of mice susceptible and resistant to hepatocarcinogenesis. Dokl Biol Sci (2010) 0.75
Forkhead box M1B is a determinant of rat susceptibility to hepatocarcinogenesis and sustains ERK activity in human HCC. Gut (2009) 1.09
5'-Methylthioadenosine administration prevents lipid peroxidation and fibrogenesis induced in rat liver by carbon-tetrachloride intoxication. J Hepatol (2001) 1.03
Comparative effects of L-methionine, S-adenosyl-L-methionine and 5'-methylthioadenosine on the growth of preneoplastic lesions and DNA methylation in rat liver during the early stages of hepatocarcinogenesis. Anticancer Res (1992) 1.01
Chemoprevention of rat liver carcinogenesis by S-adenosyl-L-methionine: a long-term study. Cancer Res (1992) 0.99
Chemoprevention by S-adenosyl-L-methionine of rat liver carcinogenesis initiated by 1,2-dimethylhydrazine and promoted by orotic acid. Carcinogenesis (1995) 0.97
Protooncogene methylation and expression in regenerating liver and preneoplastic liver nodules induced in the rat by diethylnitrosamine: effect of variations of S-adenosylmethionine:S-adenosylhomocysteine ratio. Carcinogenesis (1989) 0.96
Alcohol-preferring rats have fewer dopamine D2 receptors in the limbic system. Alcohol Alcohol (1992) 0.92
Correlation between S-adenosyl-L-methionine content and production of c-myc, c-Ha-ras, and c-Ki-ras mRNA transcripts in the early stages of rat liver carcinogenesis. Cancer Lett (1994) 0.91
Inhibition of promotion and persistent nodule growth by S-adenosyl-L-methionine in rat liver carcinogenesis: role of remodeling and apoptosis. Cancer Res (1989) 0.88
Genetic alterations in liver carcinogenesis: implications for new preventive and therapeutic strategies. Crit Rev Oncog (2000) 0.88
Transferrin and transferrin receptor gene expression and iron uptake in hepatocellular carcinoma in the rat. Hepatology (1998) 0.83
Frequent loss of heterozygosity at the Hcr1 (hepatocarcinogenesis resistance) locus on chromosome 10 in primary hepatocellular carcinomas from LFF1 rat strain. Hepatology (2001) 0.82
Inhibition by dehydroepiandrosterone of growth and progression of persistent liver nodules in experimental rat liver carcinogenesis. Int J Cancer (1995) 0.82
Dependence of benzo(a)pyrene metabolism on NADPH pool in normal and glucose-6-phosphate dehydrogenase deficient human fibroblasts. Res Commun Chem Pathol Pharmacol (1990) 0.81
Reversal by 5-azacytidine of the S-adenosyl-L-methionine-induced inhibition of the development of putative preneoplastic foci in rat liver carcinogenesis. Cancer Lett (1991) 0.81
Correlation of c-myc overexpression and amplification with progression of preneoplastic liver lesions to malignancy in the poorly susceptible Wistar rat strain. Mol Carcinog (1999) 0.80
Inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase activity and gene expression by dehydroepiandrosterone in preneoplastic liver nodules. Carcinogenesis (1995) 0.80
Reversal by ribo- and deoxyribonucleosides of dehydroepiandrosterone-induced inhibition of enzyme altered foci in the liver of rats subjected to the initiation--selection process of experimental carcinogenesis. Carcinogenesis (1988) 0.79
Analysis of epidermal growth factor receptor (EGFR) status in endometrial stromal sarcoma. Eur J Gynaecol Oncol (2012) 0.79
Mucormycosis associated with carotid cavernous fistula and cavernous carotid mycotic aneurysm. J Fla Med Assoc (1989) 0.78
The BN rat strain carries dominant hepatocarcinogen resistance loci. Carcinogenesis (1996) 0.78
Differential effects of dehydroepiandrosterone and deoxyribonucleosides on DNA synthesis and de novo cholesterogenesis in hepatocarcinogenesis in rats. Carcinogenesis (1991) 0.78
Modulation by MHC class I antigens of the biology of melanoma cells. Non-immunological mechanisms. Melanoma Res (1993) 0.78
Persistent chemopreventive effect of S-adenosyl-L-methionine on the development of liver putative preneoplastic lesions induced by thiobenzamide in diethylnitrosamine-initiated rats. Carcinogenesis (1996) 0.77
Deregulation of DNA-dependent protein kinase catalytic subunit contributes to human hepatocarcinogenesis development and has a putative prognostic value. Br J Cancer (2013) 0.77
Identification of genetic loci controlling hepatocarcinogenesis on rat chromosomes 7 and 10. Cancer Res (1999) 0.77
Genomic abnormalities in hepatocarcinogenesis. Implications for a chemopreventive strategy. Anticancer Res (1993) 0.77
c-myc amplification in pre-malignant and malignant lesions induced in rat liver by the resistant hepatocyte model. Int J Cancer (1996) 0.77
Alterations of ornithine decarboxylase gene during the progression of rat liver carcinogenesis. Carcinogenesis (1993) 0.75
Analysis of loss of heterozygosity in neoplastic nodules induced by diethylnitrosamine in the resistant BFF1 rat strain. Carcinogenesis (1999) 0.75
Implication of Bcl-2 family genes in basal and D-amphetamine-induced apoptosis in preneoplastic and neoplastic rat liver lesions. Hepatology (2000) 0.75
l-5-formyltetrahydrofolate and l-5-methyltetrahydrofolate rescue in L1210 leukemia treated with high methotrexate doses. Res Commun Chem Pathol Pharmacol (1993) 0.75
Effect of orotic acid on beta 1,4-galactosyltransferase during liver regeneration. Carcinogenesis (1993) 0.75
Increase in D2 dopamine receptors in the substantia nigra after chronic (-)-sulpiride treatment. Brain Res (1991) 0.75
The burden of HIV-associated neurocognitive disorder (HAND) in post-HAART era: a multidisciplinary review of the literature. Eur Rev Med Pharmacol Sci (2017) 0.75
Na-23 NMR spin-lattice relaxation times in rat tissues, and related modifications following CCl4 intoxication. Biochem Biophys Res Commun (1986) 0.75
Chemoprevention of rat liver carcinogenesis by S-adenosyl-L-methionine: is DNA methylation involved? Basic Life Sci (1993) 0.75
Effect of S-adenosyl-L-methionine on the development of preneoplastic foci and the activity of some carbohydrate metabolizing enzymes in the liver, during experimental hepatocarcinogenesis. Anticancer Res (1994) 0.75